Shares of Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $64.71, but opened at $62.56. Novozymes A/S shares last traded at $63.34, with a volume of 132 shares.
Wall Street Analysts Forecast Growth
Separately, Zacks Research lowered shares of Novozymes A/S from a "strong-buy" rating to a "hold" rating in a report on Monday, August 25th. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Novozymes A/S has a consensus rating of "Moderate Buy".
View Our Latest Analysis on NVZMY
Novozymes A/S Stock Performance
The stock's 50-day simple moving average is $67.68 and its 200 day simple moving average is $65.30. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.04 and a current ratio of 1.66. The company has a market capitalization of $29.39 billion, a PE ratio of 39.72, a P/E/G ratio of 1.26 and a beta of 0.93.
Novozymes A/S Cuts Dividend
The company also recently disclosed a dividend, which will be paid on Thursday, September 11th. Shareholders of record on Wednesday, September 3rd will be given a $0.1856 dividend. The ex-dividend date of this dividend is Tuesday, September 2nd. This represents a dividend yield of 88.0%. Novozymes A/S's dividend payout ratio is currently 23.42%.
Novozymes A/S Company Profile
(
Get Free Report)
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.
Further Reading
Before you consider Novozymes A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.
While Novozymes A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.